Cover of: Antisense oligodeoxynucleotides and antisense RNA |

Antisense oligodeoxynucleotides and antisense RNA

novel pharmacological and therapeutic agents
  • 252 Pages
  • 4.43 MB
  • 6752 Downloads
  • English

CRC Press , Roca Raton, Fla
Antisense nucleic acids -- Therapeutic
Statementedited by Benjamin Weiss.
SeriesPharmacology and toxicology, Pharmacology & toxicology (Boca Raton, Fla.)
ContributionsWeiss, Benjamin, 1922-
Classifications
LC ClassificationsRM666.A564 A57 1997
The Physical Object
Pagination252 p. :
ID Numbers
Open LibraryOL281346M
ISBN 100849385520
LC Control Number97183510

This book is a practical, state-of-the-art treatise on antisense oligodeoxynucleotide and antisense RNA technology and the potential application of these strategies in therapeutics. Critical analyses of the specificity of the agents are featured, and the possibility of antisense oligomers acting through non-antisense mechanisms is considered.

ISBN: OCLC Number: Description: pages: illustrations ; 26 cm. Contents: Ch. Historical Aspects of Antisense Oligodeoxynucleotides / Jean-Jacques Toulme --Ch.

Download Antisense oligodeoxynucleotides and antisense RNA FB2

es in Understanding the Pharmacological Properties of Antisense Oligonucleotides / Stanley Crooke --Ch. cokinetics of Phosphorothioate Oligonucleotides and Their Novel. Antisense oligonucleotides are synthetic polymers. Antisense oligodeoxynucleotides and antisense RNA book The monomers are chemically-modified deoxynucleotides like those in DNA or ribonucleotides like those in RNA.

There are usually only 15–20 of them, hence "oligo". Their sequence (3′ → 5′) is antisense; that is, complementary to the sense sequence of a molecule of mRNA. Antisense oligodeoxynucleotides and antisense RNA allow pharmacologists to design agents that are more predictable and selective in their actions.

This book is a practical, state-of-the-art treatise on antisense oligodeoxynucleotide and antisense RNA technology and the potential application of these strategies in : Pasta dura.

Antisense oligonucleotides (ASOs) have been validated as therapeutic agents and an important tool in molecular biology. Indeed, ASOs are used either in vitro or in vivo to generate mRNA selective knockouts. They can be used for human therapy since ASOs can inhibit specifically target genes especially whose are difficult to target with small molecules inhibitors or neutralizing by: 3.

Purchase Antisense Technology, Part A, General Methods, Methods of Delivery, and RNA Studies, Volume - 1st Edition. Print Book & E-Book. ISBNSense and antisense Oligodeoxynucleotides to Glun1 Nmdar are Cognitive Enhancers (Nootropics) and protective agents in normal and ischemic (Anoxic) conditions-In vitro study Published: J Antisense oligonucleotides (aODNs) have been used in various tissues as therapeutic agents, and as research tools for downregulating certain genes.

Antisense oligonucleotide-based Antisense oligodeoxynucleotides and antisense RNA book involves downregulation of gene expression. RNA-based drugs that include antisense oligonucleotides bear great therapeutic potential toward treatment of various diseases by altering RNA and/or reducing, restoring, and modifying protein expression through multiple molecular mechanisms.

Antisense Receptor Targets: J. Garzón, I. de Antonio, and P. Sánchez-Blázquez, In vivo Modulation of G-proteins and Opioid Receptor Function by Antisense Oligodeoxynucleotides.J. Karle and M.

Nielsen, Targeting Brain GABA-A Receptors with Antisense Oligonucleotides: Implications for Epilepsy.D. Mohuezy, X. Tang, and M.I.

Details Antisense oligodeoxynucleotides and antisense RNA FB2

Phillips, Delivery of Antisense DNA by Vectors for Prolonged. Antisense-oligonucleotides block translation of the mRNA or induce its degradation by RNase H, while ribozymes and DNA enzymes possess catalytic activity and cleave their target RNA.

Antisense RNA (asRNA), also referred to as antisense transcript, natural antisense transcript (NAT) or antisense oligonucleotide, is a single stranded RNA that is complementary to a protein coding messenger RNA (mRNA) with which it hybridizes, and thereby blocks its translation into protein.

asRNAs (which occur naturally) have been found in both prokaryotes and eukaryotes, antisense. As a frontier method, these new technologies may be used to combat diseases, as well as to study gene functions by interfering in the genetic flow of information from DNA to RNA to protein.

In the following article I will describe antisense techniques, starting with the chemical nature of the antisense oligodeoxynucleotides and some of the most.

Selective gene inhibition by antisense oligodeoxynucleotide (AS-ODN) or by small interference RNA (siRNA) therapeutics promises the treatment of diseases that cannot be cured by conventional drugs. However, antisense therapy is hindered due to poor stability in physiological fluids and limited intracellular uptake.

To address these problems, a ligand targeted and sterically stabilized. The complimentary nucleic acid sequence can be either a synthetic oligonucleotide, often oligodeoxy ribonucleotides (ODN) of less than 30 nucleotides, or longer antisense RNA (aRNA) sequences.

Toulme, J. and Helene, C. () Antimessenger oligodeoxynucleotides: an alternative to antisense RNA for artificial regulation of gene expression-a review. Gene. Antisense Oligonucleotides Antisense oligonucleotides ("ASOs") are synthetic polymers. The monomers are chemically-modified deoxynucleotides like those in DNA or ribonucleotides like those in RNA.; There are usually only 15–30 of them, hence "oligo".

Their sequence (3′ → 5′) is antisense; that is, complementary to the sense sequence of a molecule of mRNA.

Antisense Nucleic Acid. Cite this entry as: () Antisense Oligodeoxynucleotides. In: Schwab M. (eds) Encyclopedia of Cancer.

Antisense oligodeoxynucleotides (ODNs) bind messenger RNA molecules in a sequence-specific manner preventing their translation and thus knocking down expression of the encoded protein product. Novel therapies based on this strategy are currently under investigation in various neoplastic, inflammatory, and infectious diseases.

Book, Internet Resource: Selection of potent oligonucleotide sequences for antisense experiments --Effects of centrally administered antisense oligodeoxynucleotides on feeding behavior and hormone secretion --Blockage of neuropathic pain by antisense targeting of # Antisense RNA\/span>\n \u00A0\u00A0\u00A0\n schema:about\/a.

One of the inherent problems in the use of antisense oligodeoxynucleotides to ablate gene expression in cell cultures is that the stringency of hybridization in vivo is not subject to control and may be sub-optimal.

Consequently, phosphodiester or phosphorothioate antisense effectors and non-targeted cellular RNA may form partial hybrids which. Modulating Gene Expression by Antisense Oligonucleotides to Understand Neural Functioning addresses the origins of that controversy and determines whether the nervous system is a privileged site for antisense oligonucleotide action and not subject to.

ODNBase is a database of antisense oligodeoxynucleotides targeted to mammalian mRNAs that were reported in the literature. It includes the oligo sequences tested, the measured effectiveness, the RNA that was targeted, the type of measurement assay used, the oligo concentration applied, and the reference for each oligo.

Antisense oligonucleotides (ASOs) are DNA oligos, typically 15–25 bases long, designed in antisense orientation to the RNA of interest. Hybridization of the ASO to the target RNA mediates RNase H cleavage of the RNA, which can inhibit the function of non-coding RNAs (e.g., miRNAs, siRNAs, piRNAs, snoRNAs, snRNAs, exRNAs, scaRNAs and lncRNAs) or prevent protein translation of mRNAs.

Antisense Oligodeoxynucleotides Directed against the Na‐Ca Exchanger mRNA Ryszard Kole, Antisense oligonucleotides and RNAs as modulators of pre-mRNA splicing, Antisense Technology Part A: General Methods, Methods of Delivery, and RNA Studies, /S(00), (), (). Crossref. Extensively revised and updated, Antisense Drug Technology: Principles, Strategies, and Applications, Second Edition reflects the logarithmic progress made in the past four years of oligonucleotide-based therapies, and, in particular, antisense therapeutics and research.

Interpreting lessons learned from the clinical trials of first generation drugs, the book evaluates the technology as. Oligodeoxynucleotides: Antisense Inhibitors of Gene Expression (TOPICS ON MOLECULAR AND STRUCTURAL BIOLOGY): Medicine & Health Science Books @. Caged antisense oligodeoxynucleotides (asODNs) are synthesized by linking two ends of linear oligodeoxynucleotides using a photocleavable linker.

Two of them (H30 and H40) have hairpin-like structures which show a large difference in thermal stability (ΔT m =.

Download instantly Antisense Technology, Part A, General Methods, Methods of Delivery, and RNA Studies By Abelson, John N., Simon, Melvin I.

It is ebook in PDF format. It is ebook in PDF format. ISBN ISBN Effects of antisense oligodeoxynucleotide targeting of the alpha(2B)-adrenergic receptor messenger RNA in the central nervous system.

Kintsurashvili E(1), Gavras I, Johns C, Gavras H. Author information: (1)Hypertension and Atherosclerosis Section, Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. 3´ G U A C 5´ Antisense RNA.

Description Antisense oligodeoxynucleotides and antisense RNA EPUB

The second strand is called the antisense strand because its sequence of nucleotides is the complement of message sense. Figure Antisense RNA. When mRNA forms a duplex with a complementary antisense RNA sequence, translation is blocked. Antisense oligodeoxynucleotides (As-ODN) with the sequence 5’TAGGGTTAGACAA3’, which can recognize the RNA template region of telomerase, and missense oligodeoxynucleotide (Ms-ODN) with the sequence 5’TGTAAGGAACTAG-3’ were synthesized by Beijing SBS Biotechnology Engineering Company using the DNA synthesizer.Antisense oligodeoxynucleotides targeted to bcr-abl are potential ex vivo purging agents for use with autologous bone marrow transplantation in the treatment of chronic myeloid leukemia (CML).

breakpoint RNAs can be more effectively targeted than b3a2 sequence RNAs both in vitro and in vivo and suggest that RNA secondary structure may be a.Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA).

ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockade, and exon content modulation through splicing site binding on pre-mRNA.